drugset / Trial / NCT03441100
TCR-engineered T Cells in Solid Tumors: IMA202-101
NaSingle-groupOpen-labelTreatment
Summary
The study purpose is to establish the safety and tolerability of IMA202 product in patients with solid tumors that express melanoma-associated antigen 1 (MAGEA1).
Timeline
- Start
- 2019-05-02
- Primary completion
- 2022-06-17
- Completion
- 2023-03-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMA202 | Cell therapy | — | Intravenous |